UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Position in Inari Medical, Inc. (NASDAQ:NARI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 3.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,270,991 shares of the company's stock after selling 48,011 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 2.17% of Inari Medical worth $52,416,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NARI. Lighthouse Investment Partners LLC purchased a new stake in Inari Medical during the 2nd quarter valued at approximately $2,145,000. Aigen Investment Management LP purchased a new stake in shares of Inari Medical during the third quarter worth approximately $428,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Inari Medical during the third quarter worth approximately $1,397,000. Integral Health Asset Management LLC lifted its holdings in shares of Inari Medical by 100.0% during the second quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company's stock worth $19,260,000 after purchasing an additional 200,000 shares during the period. Finally, Jennison Associates LLC boosted its holdings in shares of Inari Medical by 63.2% in the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock valued at $65,021,000 after acquiring an additional 610,468 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company's stock.

Insider Buying and Selling

In other Inari Medical news, Director William Hoffman sold 60,000 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $51.16, for a total value of $3,069,600.00. Following the sale, the director now directly owns 501,233 shares of the company's stock, valued at approximately $25,643,080.28. This trade represents a 10.69 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the company's stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares of the company's stock, valued at approximately $22,265,500. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 186,000 shares of company stock worth $8,990,990. 10.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

NARI has been the topic of several recent analyst reports. Robert W. Baird boosted their target price on Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 29th. Leerink Partners initiated coverage on Inari Medical in a research report on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price objective for the company. Deutsche Bank Aktiengesellschaft initiated coverage on Inari Medical in a report on Friday, August 9th. They issued a "buy" rating and a $68.00 target price for the company. Stifel Nicolaus started coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 price target for the company. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Inari Medical in a research note on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $58.89.

Inari Medical Stock Performance

NARI stock traded up $0.16 on Wednesday, reaching $51.71. The company had a trading volume of 342,407 shares, compared to its average volume of 975,105. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13. The company has a market cap of $3.03 billion, a P/E ratio of -38.18 and a beta of 0.97. The company's fifty day moving average is $46.67 and its 200 day moving average is $47.62.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.